Today: 9 June 2026
Lyft Stock Price Today: Shares Steady After Jefferies Cut Flags U.S. Slowdown and Waymo Risk

Lyft Stock Price Today: Shares Steady After Jefferies Cut Flags U.S. Slowdown and Waymo Risk

New York, March 20, 2026, 18:42 EDT

Lyft shares ticked up 0.7% to $13.47 late Friday in U.S. trading. The small gain followed Jefferies’ decision a day earlier to trim its price target to $15 from $15.50, sticking with a Hold rating. The firm cautioned that sluggish U.S. rideshare growth and Waymo’s rollout might drag on the stock.

It’s a key point for Lyft, which has been pitching investors on buybacks, a move into Europe, and lining up fresh AI and driverless-car deals to counter the squeeze in its main U.S. operations. But with Uber ratcheting up its robotaxi push, the argument is a harder sell—analysts are openly doubting Lyft’s ability to keep its foothold at home.

Jefferies flagged Lyft’s slowing U.S. rideshare numbers—growth dropped to 8.5% year over year in Q4 2025, down sharply from 20% back in Q1 2024. Even if things steady from here, analysts at the brokerage see 1% to 3% downside risk for Lyft’s 2026 and 2027 bookings, which covers the value of trips and transactions running through its platform. Waymo, meanwhile, saw weekly paid rides jump to 450,000 by December 2025, up from 150,000 in October 2024. That ramp could trim 0.4% to 0.6% off Lyft’s bookings growth for 2026 and 2027, according to Jefferies.

Mark Giarelli at Morningstar didn’t mince words on Friday, calling out a sharp divide: “The core strategic divide between Uber and Lyft is network depth versus price competition,” he wrote. Lyft, he noted, has just a single Waymo arrangement going in Nashville, while Uber’s setup with autonomous-vehicle partners goes further. Morningstar, Inc.

Lyft is leaning into its own tech effort. The company announced Monday it plans to deploy Nvidia’s AI tools for smarter rider-driver pairing, mapping upgrades, and support systems for upcoming autonomous fleets. Siddharth Patil, who heads rideshare and marketplace at Lyft, called the AI infrastructure the “backbone of modern mobility.” Lyft, Inc.

Uber on Thursday announced plans to invest as much as $1.25 billion in Rivian, aiming to roll out 10,000 autonomous R2 SUVs starting in 2028. The move stacks on top of Uber’s existing partnerships with Waymo, Baidu, Lucid, and Nvidia—clear evidence of the accelerating robotaxi race.

But Lyft faces pressure to prove its fresh partnerships actually boost demand, rather than just improve the narrative. Jefferies trimmed its 2027 bookings and EBITDA estimates, now sitting 3% and 7% under the consensus, and kept its price target only slightly higher than Friday’s close.

This isn’t a fresh worry. Back in February, Lyft put out a first-quarter adjusted core profit outlook that fell short, blaming tough winter storms and higher seasonal costs. The company also surprised markets with an unexpected 2025 operating loss, wiping out 16% from its shares in after-hours trade—despite announcing a hefty $1 billion buyback. “Uber, Lyft’s main competitor, is growing earnings much faster than Lyft,” said Andrew Rocco, stock strategist at Zacks Investment Research at the time. Reuters

Lyft isn’t building from the ground up. The company turned in record results for the fourth quarter and all of 2025, pulled in $1.12 billion in free cash flow, and said its 2027 goals remain in play. Still, Jefferies kept its Hold, and a Friday note from Morningstar flagged that investors want firmer signs U.S. ride demand will accelerate.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Stock Market Today: Dow, S&P 500, Nasdaq Tumble as Iran Conflict Sends Oil to 2022 High and Erases Fed Cut Hopes
Previous Story

Stock Market Today: Dow, S&P 500, Nasdaq Tumble as Iran Conflict Sends Oil to 2022 High and Erases Fed Cut Hopes

Jury Finds Elon Musk Liable for Misleading Twitter Investors in $44 Billion Buyout Fight
Next Story

Jury Finds Elon Musk Liable for Misleading Twitter Investors in $44 Billion Buyout Fight

Go toTop